Literature DB >> 17636756

Antibiotics for whooping cough (pertussis).

S Altunaiji1, R Kukuruzovic, N Curtis, J Massie.   

Abstract

BACKGROUND: Whooping cough is a highly contagious disease. Infants are at highest risk of severe disease and death. Erythromycin for 14 days is currently recommended for treatment and contact prophylaxis, but is of uncertain benefit.
OBJECTIVES: To study the benefits and risks of antibiotic treatment of and contact prophylaxis against whooping cough. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), the Database of Abstracts of Reviews of Effects (DARE) (The Cochrane Library Issue 1, 2007); MEDLINE (January 1966 to March 2007); EMBASE (January 1974 to March 2007). SELECTION CRITERIA: All randomised and quasi-randomised controlled trials of antibiotics for treatment of, and contact prophylaxis against, whooping cough. DATA COLLECTION AND ANALYSIS: Three to four review authors independently extracted data and assessed the quality of each trial. MAIN
RESULTS: Thirteen trials with 2197 participants met the inclusion criteria: 11 trials investigated treatment regimens; 2 investigated prophylaxis regimens. The quality of the trials was variable.Short-term antibiotics (azithromycin for three to five days, or clarithromycin or erythromycin for seven days) were as effective as long-term (erythromycin for 10 to 14 days) in eradicating Bordetella pertussis (B. pertussis) from the nasopharynx (relative risk (RR) 1.02, 95% confidence interval (CI) 0.98 to 1.05), but had fewer side effects (RR 0.66, 95% CI 0.52 to 0.83). Trimethoprim/sulfamethoxazole for seven days was also effective. Nor were there differences in clinical outcomes or microbiological relapse between short and long-term antibiotics. Contact prophylaxis of contacts older than six months of age with antibiotics did not significantly improve clinical symptoms or the number of cases developing culture-positive B. pertussis. AUTHORS'
CONCLUSIONS: Although antibiotics were effective in eliminating B. pertussis, they did not alter the subsequent clinical course of the illness. There is insufficient evidence to determine the benefit of prophylactic treatment of pertussis contacts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636756     DOI: 10.1002/14651858.CD004404.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  31 in total

1.  Peptidoglycan Recognition Protein 4 Suppresses Early Inflammatory Responses to Bordetella pertussis and Contributes to Sphingosine-1-Phosphate Receptor Agonist-Mediated Disease Attenuation.

Authors:  Ciaran Skerry; William E Goldman; Nicholas H Carbonetti
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

Review 2.  Bordetella pertussis: new concepts in pathogenesis and treatment.

Authors:  Nicholas H Carbonetti
Journal:  Curr Opin Infect Dis       Date:  2016-06       Impact factor: 4.915

Review 3.  [Recent progress in clinical research on pertussis].

Authors:  Dan-Xia Wu; Qiang Chen; Kun-Ling Shen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-09

Review 4.  Novel therapies for the treatment of pertussis disease.

Authors:  Karen M Scanlon; Ciaran Skerry; Nicholas H Carbonetti
Journal:  Pathog Dis       Date:  2015-09-21       Impact factor: 3.166

5.  Reduction of Pertussis Inflammatory Pathology by Therapeutic Treatment With Sphingosine-1-Phosphate Receptor Ligands by a Pertussis Toxin-Insensitive Mechanism.

Authors:  Ciaran Skerry; Karen Scanlon; Jeremy Ardanuy; Drew Roberts; Li Zhang; Hugh Rosen; Nicholas H Carbonetti
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

Review 6.  Clinically Diagnosing Pertussis-associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report.

Authors:  Abigail Moore; Anthony Harnden; Cameron C Grant; Sheena Patel; Richard S Irwin
Journal:  Chest       Date:  2018-10-12       Impact factor: 9.410

Review 7.  Coughing precipitated by Bordetella pertussis infection.

Authors:  Matthew Hewitt; Brendan J Canning
Journal:  Lung       Date:  2010-01       Impact factor: 2.584

8.  Pertussis in early life: underdiagnosed, severe, and risky disease. A seven-year experience in a pediatric tertiary-care hospital.

Authors:  Chiara Di Camillo; Anna Chiara Vittucci; Livia Antilici; Claudia Ciarlitto; Giulia Linardos; Carlo Concato; Laura Lancella; Alberto Villani
Journal:  Hum Vaccin Immunother       Date:  2020-08-05       Impact factor: 3.452

Review 9.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

Review 10.  Symptomatic treatment of the cough in whooping cough.

Authors:  Kay Wang; Silvana Bettiol; Matthew J Thompson; Nia W Roberts; Rafael Perera; Carl J Heneghan; Anthony Harnden
Journal:  Cochrane Database Syst Rev       Date:  2014-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.